Today: 20 March 2026
Subscribe
Browse Category

Healthcare News 9 August 2025 - 9 December 2025

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie shares closed at $227.70 on November 28, near record highs after a 31.7% year-to-date gain. The company secured a major reimbursement win in Canada for Skyrizi in ulcerative colitis. Institutional investors reported changes in AbbVie holdings. Analysts questioned whether the stock remains undervalued after its recent rally.
29 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Novo Nordisk slashed the self-pay price of Wegovy and most Ozempic doses from $499 to $349 per month, effective Nov. 17, 2025. New patients can access starter doses for $199 monthly for two months. The move follows White House deals expanding Medicare and Medicaid coverage for obesity drugs and comes as telehealth firms launch competing $199 offers.
17 November 2025
·
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals said its fibromyalgia drug TONMYA is now available by prescription across the U.S. Shares of Tonix (NASDAQ: TNXP) rose nearly 8% in early trading, reaching $17.16. TONMYA, approved by the FDA in August 2025, is the first new fibromyalgia therapy in over 15 years. The company reported the launch in a Form 8-K filing with the SEC.
17 November 2025
··
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings reported a 62% complete response rate at 6 months in its pivotal Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk, BCG-unresponsive NMIBC with CIS. The company enrolled 125 patients, above target. Shares surged as much as 62% pre-market after the update. Safety data showed 42% of patients had treatment-related adverse events, mostly mild.
11 November 2025
···
Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys (FEMY) Skyrockets on Breakthrough Birth Control Trial News – Is This Women’s Health Innovator a Game-Changer?

Femasys shares jumped as much as 25% pre-market Nov. 3 after the company won FDA approval to begin the final phase of its FemBloc pivotal trial and secured up to $58 million in new financing. FEMY closed up 8% at $0.69 after hitting $0.79 intraday. FemBloc recently gained CE Mark and approvals in the UK and New Zealand. Q2 sales rose 85% to $0.41 million, with a net loss of $4.59 million.
3 November 2025
·
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics shares soared over 142% to $4.53 on Oct. 9 after announcing an expanded manufacturing partnership with SanyoSeiko. Trading volume hit 40 million shares, far above the 154,000 average. The company, which has no product revenue and only $5.7 million in cash, recently cut its workforce by 90%. Symphony, its lead diagnostic product, is not yet FDA-cleared.
9 October 2025
··
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer shares surged 15% from Sept. 26 to Oct. 1, closing at $27.21 after a major drug-pricing deal with the Trump administration. The agreement, announced Sept. 30, ties U.S. Medicaid prices to those in other wealthy countries in exchange for tariff relief. Pfizer also agreed to buy obesity-drug developer Metsera for $4.9 billion. Market cap stands near $155 billion, with a dividend yield around 6%.
2 October 2025
···
Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

Biotech & Health Bombshells: FDA Greenlights, Clinical Breakthroughs & Global Health Milestones (Aug 8–9, 2025)

The FDA approved Boehringer Ingelheim’s lung cancer drug Hernexeos and a companion diagnostic on Aug 8, citing trial data showing tumor shrinkage in 75% of eligible patients. The agency restricted Bluebird Bio’s Skysona gene therapy to patients lacking a matched donor due to blood cancer risk. Stealth BioTherapeutics’ Barth syndrome drug was rejected for a third time. The FDA declared the U.S. IV saline shortage over.
9 August 2025
··
1 2

Stock Market Today

  • European Stocks Rise as Oil Prices Drop and Rate Hike Bets Grow
    March 20, 2026, 5:11 AM EDT. European stocks rebounded on Friday, led by banking and construction sectors, as oil prices eased from recent highs above $119 a barrel. The decline followed U.S. signals about possibly lifting sanctions on Iranian crude to reduce energy costs. Central banks across Europe, including the European Central Bank (ECB) and Bank of England (BoE), held interest rates steady amid uncertainty from the U.S.-Iran conflict but traders increased bets on further rate hikes later this year. The ECB highlighted inflation risks tied to the war, while the BoE's unanimous hold hinted at readiness to act. Meanwhile, Unilever disclosed talks to sell part of its foods business to McCormick & Company, adding corporate activity amid market shifts.
Go toTop